Experiences with a new regional citrate anticoagulation protocol for continuous venovenous hemofiltration using a phosphate containing replacement solution in critically ill patients

Not Applicable

Completed

• Conditions: Acute kidney injury; Critical illness; Renal and Urogenital - Kidney disease

• Registration Number: ACTRN12614001000695
• Lead Sponsor: Intensive Care Unit, Queen Elizabeth Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-09-16
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

All patients who underwent CVVH using Prismocitrate 18/0 and Phoxilium during the study period

Exclusion Criteria

Insufficient data for analysis

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Hemofilter life span as determined by time to circuit clotting criteria reached and no more than 72 hours[Circuit clotting criteria: hourly inspections for visible extracorporeal circuit / filter clotting, or transmembrane pressure >450mmHg, up to a maximum of 72 hours<br>]